Otonomy, Inc. Logo
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
October 12, 2021 07:30 ET | Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
Otonomy, Inc. Logo
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
April 05, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
March 25, 2021 07:30 ET | Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy, Inc. Logo
Otonomy to Participate in Three Upcoming Investor Conferences
February 25, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
February 22, 2021 07:00 ET | Otonomy, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 17, 2021 07:30 ET | Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 11, 2021 16:17 ET | Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...
Otonomy, Inc. Logo
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
November 30, 2020 07:30 ET | Otonomy, Inc.
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
Otonomy, Inc. Logo
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 13, 2020 16:01 ET | Otonomy, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Pricing of $60.1 Million Public Offering
July 09, 2020 09:00 ET | Otonomy, Inc.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...